比索洛尔对慢性阻塞性肺疾病合并心力衰竭患者心肺功能及炎症因子表达的影响研究

目的研究比索洛尔对慢性阻塞性肺疾病合并心力衰竭患者的心肺功能和炎症因子表达的影响。方法选择2015年7月～2017年8月来我院治疗的慢性阻塞性肺疾病合并心力衰竭患者34例,根据治疗方式不同可分成对照组和观察组两组。给予对照组患者常规慢梗阻合并心力衰竭的药物;观察组患者则是在此基础上再加以比索洛尔药物治疗。观察两组患者在治疗前后的心肺功能、炎症因子水平。结果两组患者在治疗后的心肺功能和炎症因子水平比较,差异有统计学意义(P 0.05)。观察组患者在治疗后的肺功能指标和心功能指标中的左心室射血分数都要明显高于对照组患者;观察组患者在治疗后的心功能指标(除左心室射血分数外)则要明显低于对照组患者;观察组患者在治疗后的炎症因子水平也要明显低于对照组患者。结论对慢性阻塞性肺疾病合并心力衰竭患者使用比索洛尔可以明显改善患者心肺功能,降低患者的炎症因子水平,增强了患者抵抗炎症的信心,在临床上应给予使用。     

比索洛尔在慢性阻塞性肺疾病肺心病心力衰竭治疗中的应用效果评价

目的评价比索洛尔在慢性阻塞性肺疾病肺心病心力衰竭治疗中的应用效果。方法选取我院2012年1月至2014年10月收治的慢性阻塞性肺疾病(COPD)肺心病心力衰竭患者96例,按照随机数字表法将所有患者分为研究组和对照组,每组48例,对照组实施常规内科方法进行治疗,研究组联合应用比索洛尔进行治疗。比较两组临床效果以及治疗前后静息心率(RHR)、右心室舒张期内径(RV)、肺动脉收缩压(PASP)、左心室射血分数(LVEF)。结果研究组治疗后RHR、RV、PASP以及LVEF均较对照组治疗后改善更加显著,差异具有统计学意义(P<0.05)。结论采用比索洛尔治疗慢性阻塞性肺疾病肺心病心力衰竭可以取得比较显著的临床效果,明显的改善患者的心功能,能够在临床上大力的推广应用。     

比索洛尔对社区慢性阻塞性肺疾病(COPD)合并慢性心力衰竭(CHF)患者疗效及安全性分析

目的:探讨比索洛尔对社区慢性阻塞性肺疾病(COPD)合并慢性心力衰竭(CHF)患者疗效及安全性。方法:将67例COPD合并CHF患者按照治疗方法随机地分为对照组(n=33)与观察组(n=34),两组均采用强心、利尿等抗心衰常规治疗及吸氧、化痰,观察组在此基础上联合比索洛尔进行治疗。比较两组临床疗效及治疗前后心、肺功能水平、不良反应发生率。结果:(1)观察组临床总有效率显著高于对照组(P0.05);(2)观察组治疗后LVEF、FEV1及FEV1/FVC水平均显著高于治疗前及对照组治疗后(P0.05~0.01);(3)两组不良反应发生率差异无统计学意义(P0.05)。结论:比索洛尔对社区COPD合并CHF患者的临床疗效显著,安全性较高,应在临床上进行推广。     

比索洛尔与福辛普利治疗慢性阻塞性肺疾病合并慢性心力衰竭患者的临床效果与药理作用

目的 探讨比索洛尔与福辛普利治疗慢性阻塞性肺疾病合并慢性心力衰竭患者的临床效果与药理作用。方法 纳入我院2021年1～10月收治80例慢性阻塞性肺疾病合并慢性心力衰竭患者,利用随机分组法分为研究组以及对照组,各40例。对照组使用富马酸比索洛尔片进行治疗,研究组在对照组基础上为患者服用福辛普利进行口服治疗,观察两组患者的心肺功能指标、炎性指标、治疗效果以及生存质量。结果 治疗前,两组患者的心肺功能指标比较,差异无统计学意义(P> 0.05);治疗后,两组患者LVEF、LVEDd、FEV₁/FVC、VC指标均发生改变,且研究组患者的相关数据更加理想(P <0.05)。治疗前,两组患者的IL-17、CRP表达情况比较,差异无统计学意义(P> 0.05);治疗后,研究组患者的IL-17、CRP水平低于对照组,差异有统计学意义(P <0.05)。研究组患者治疗有效率为92.50%,高于对照组的72.50%,差异有统计学意义(χ²=5.541,P <0.05)。研究组治疗后的躯体功能、社会功能、心理功能、物质功能评分发分别为...     

β受体阻滞剂治疗慢性心力衰竭合并慢性阻塞性肺病的临床观察

目的探讨β受体阻滞剂在慢性心力衰竭并慢性阻塞性肺疾病治疗中的应用效果。方法选择本院2012～2013年收治的65例慢性心力衰竭并慢性阻塞性肺疾病患者,接受富马酸比索洛尔治疗,另以同期仅接受强心、镇静、止咳等常规治疗的30例患者为对照组,并对两组患者的血气分析和超声心动指标变化及临床疗效和不良反应进行比较。结果治疗前两组各项临床指标间差异无统计学意义（P〉0．05）,治疗12周后,两组各项指标均获改善（P〈0．05）,且观察组的PaO2、PaCO2、SaO2、LVESD、LVEDD和LVEF等指标均优于对照组（P〈0．05）,两组总有效率分别为89．2％和70．0％（P〈0．05）,均未见明显不良反应。结论富马酸比索洛尔治疗慢性心力衰竭并慢性阻塞性肺疾病的临床效果显著,可快速改善患者的症状,安全,值得推广。     

比索洛尔治疗51例高龄老年COPD合并心绞痛的疗效观察

目的 观察比索洛尔(康忻)在治疗高龄老年慢性阻塞性肺疾病(COPD)合并心绞痛治疗效果及机制.方法 51例高龄COPD合并心绞痛患者在常规治疗基础上服用比索洛尔,疗程为6周,同时设对照组.观察2组临床症状、心电图、心率等变化.结果 比索洛尔治疗组在临床症状、心电图、降低心率等指标方面优于对照组(P<0.05),对比索洛尔在治疗COPD合并心绞痛的高龄老年患者提供了很好的依据.结论 比索洛尔治疗老年COPD合并心绞痛治疗安全、有效、耐受性好.     

比索洛尔在慢性心力衰竭患者中的临床应用研究

目的 探讨比索洛尔在慢性心力衰竭患者中的应用效果.方法 80例确诊的慢性心力衰竭患者随机分为观察组和对照组.观察组和对照组均给予常规治疗,观察组同时给予比索洛尔治疗.观察两组患者肾素活性及左室功能改变情况.结果 观察组治疗后肾素水平、左室舒张末内径显著低于对照组治疗后,差异有统计学意义(P<0.05);观察组治疗后左室射血分数显著高于对照组治疗后,差异有统计学意义(P<0.05).观察组总有效率高于对照组,差异有统计学意义(P<0.05).结论 比索洛尔能够显著改善慢性心力衰竭患者心功能,抑制肾素活性,临床效果显著.     

慢性阻塞性肺疾病合并慢性心力衰竭高龄患者的临床护理干预

目的探讨临床护理干预对慢性阻塞性肺疾病（COPD）合并慢性心力衰竭高龄患者的应用疗效。方法选取本院2009年4月～2011年11月收治的67例慢性阻塞性肺疾病合并慢性心力衰竭高龄患者,将其随机分为两组,其中,33例患者采用常规护理作为对照组,34例患者采用护理干预作为观察组。检测并比较所有患者护理干预治疗后的临床指标。结果护理干预后,观察组患者在体力限制评分、社会限制评分、情绪评分、症状评分等几个方面均明显低于对照组,观察组患者的住院时间明显少于对照组,观察组患者的心率、左室舒张末径、脑利钠肽（BNP）均明显低于对照组,观察组左室射血分数、E/A比值、用力肺活量（FVC）、第一秒用力呼出量占肺活量比值（FEV1.0/FVC）均明显高于对照组,差异均有统计学意义（P〈0.05）。结论有效的护理干预可以明显改善慢性阻塞性肺疾病合并慢性心衰高龄患者的心肺功能,提高生活质量,缩短治疗时间。     

卡维地洛与比索洛尔治疗慢性心力衰竭的疗效观察

目的观察卡维地洛与比索洛尔治疗慢性心力衰竭的疗效。方法选取本院收治的慢性心力衰竭患者86例,分为比索洛尔组与维地洛组。观察两组的疗效及各项指标。结果治疗后,两组疗效比较差异无统计学意义(P>0.05);两组治疗后超声心动图指标左心室舒张末期容积、左心室收缩末期容积、左心室射血分数与治疗前相比,差异均有统计学意义(P<0.05);两组治疗前后血压、收缩压和舒张压相比,差异均有统计学意义(P<0.05)。结论比索洛尔和卡维地洛均能显著改善心力衰竭患者的心功能,临床可以推广应用。     

比索洛尔与米力农治疗慢性肺源性心脏病的对比观察

目的：比较比索洛尔与米力农治疗慢性肺源性心脏病的临床效果。方法选择于本院治疗的慢性肺源性心脏病患者120例,将其随机分为比索洛尔组（60例）和米力农组（60例）,比索洛尔组采用比索洛尔治疗,米力农组采用米力农治疗,观察两组患者的治疗效果及治疗前后各项指标的变化。结果治疗后比索洛尔组患者的6 min步行距离、心率均大于米力农组,差异有统计学意义（P〈0.05）;比索洛尔组不良反应发生率低于米力农组,差异有统计学意义（P〈0.05）;米力农组患者的心功能、血气指标优于比索洛尔组,差异有统计学意义（P〈0.05）。结论在慢性肺源性心脏病的治疗中,比索洛尔与米力农疗效均较好,但也均存在局限性,临床在选用时应根据患者的具体情况,选择合适的药物治疗。     

Emerging treatment for chronic migraine and refractory chronic migraine

Introduction: Chronic migraine (CM), the suffering of 15 or more headache days with at least 8 of these migraine days, afflicts 1.3% - 5.1% of the global population. CM is the most common disorder faced by experts in tertiary headache centers. When resistant to conventional medical treatment and prophylactic medication this condition is known as refractory chronic migraine (RCM). RCM is one of the greatest challenges in headache medicine. Areas covered: State-of-the-art and future medical treatments of chronic migraine include: OnabotulinumtoxinA, antiepileptic drugs (Levetiracetam, Magnesium valproate hydrate, Lacosamide, BGG-492), 5-HT agonists (Lasmiditan, NXN-188, novel delivery systems of Sumatriptan, a well-established drug treatment for acute migraine), CGRP receptor antagonists (BMS-927711), ML-1 agonists (Ramelteon), orexin receptor antagonist (MK-6096), plant-derived compound (LLL-2011) and other multitarget drugs such as Tezampanel, Tonabersat, intranasal carbon dioxide and BOL-148. The role for neuromodulation, the application of targeted electrical stimulation, will be examined. Expert opinion: Medication overuse headache (MOH) is now recognized to be a major factor in many cases of both chronic and refractory chronic migraine. MOH must be addressed prior to evaluating the effectiveness of new preventative and prophylactic treatment approaches. Innovative new drugs and electrical neuromodulation are promising CM treatments. Future studies must carefully screen patients and acquire data that can lead to personalized, tailored treatment strategies.     

Treatment of chronic prostatitis/chronic pelvic pain syndrome

Acceptance of the National Institutes of Health definition of Category III Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) and the development and validation of the Chronic Prostatitis Symptom Index has stimulated significant research into treatment of this condition. Evidence-based suggestions for treatment include the following. (i) Antimicrobials cannot be recommended for men with longstanding, previously treated CP/CPPS. (ii) Alpha-blockers can be recommended as first-line medical therapy, particularly in alpha-blocker-na?ve men with moderately severe symptoms who have relatively recent onset of symptoms. (iii) Alpha-blockers cannot be recommended in men with longstanding CP/CPPS who have tried and failed alpha-blockers in the past. And (iv) anti-inflammatory therapy, finasteride and pentosan polysulfate are not recommended as primary treatment; however, they may have a useful adjunctive role in a multimodal therapeutic regimen. Early data on herbal therapies, particularly quercetin and cernilton, are intriguing, but larger multicentre, randomised, placebo-controlled trials are required before a high level of evidence recommendation can be made on its use. At this time, surgery (including minimally invasive) is recommended only for definitive indications and not generally for CP/CPPS.     

治疗性疫苗应用于慢性/感染性疾病治疗的研究

治疗性疫苗诱导已患病个体特异性T细胞反应,增强保护性细胞免疫应答,清除病原体或异常细胞,使许多慢性/感染性疾病得以治疗,受到了医学界的广泛关注。本资料就各类治疗性疫苗的作用机理、存在问题以及研究趋势等做一全面的分析。     

Metabolism of procainamide in patients with chronic heart failure,chronic respiratory failure and chronic renal failure

Summary Fractional hydrolysis and acetylation of procainamide, acetylation of procainamide-derived p-aminobenzoic acid and plasma hydrolysis of procaine were studied in 20 patients with chronic heart failure (CHF), 20 patients with chronic respiratory insufficiency (CRI) and 20 patients with chronic renal failure (RF). The results were compared with those obtained in a group of 20 normal volunteers. Hydrolysis of procainamide and procaine were reduced in patients with CHF and CRI, but not in patients with RF. Moreover, more marked decreases in procainamide and procaine hydrolysis were seen in subgroups with secondary hepatic dysfunction. The diminution of hydrolysis of procainamide was not paralleled by changes in acetylation of procainamide or p-aminobenzoic acid. It is concluded that in patients with hepatic involvement secondary to advanced CHF or CRI, hepatic and plasmatic hydrolysis activity is decreased to a degree equivalent to primary liver failure.Preliminary results presented at the Seventy-eight Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Dallas, Texas 1977.Supported in part by a grant from Centre de Recherche Merrell International.Recipient of a Merck Sharp & Dohme International Fellowship in Clinical Pharmacology.     

Descending facilitation in chronic stress and chronic pain state]

The spino-thalamic tract consists of two systems; the lateral system terminates in the somato-sensory cortex, and participates in the sensory discrimination of pain, and the medial system terminates in the anterior cingulated cortex (ACC) and insular cortex (IC) to mediate affective components of pain. Persistent pain induces plastic changes in cortical neurons, especially in the ACC and IC. Activation of these neurons is transmitted to the periaqueductal gray and rostroventromedial medulla (RVM) (descending pain control system). This system has long been considered to exert descending inhibition, but recent studies revealed that it also causes facilitation in certain pathological conditions. A variety of stressful stimuli have been shown to affect pain sensitivity. We demonstrated that chronic restraint stress induced thermal hyperalgesia in rats, in which phosphorylated ERK and levels of tryptophan hydroxylase, a key enzyme of 5-HT production, were increased in the RVM. 5HT released from the bulbospinal neurons may exert facilitatory effects on spinal nociceptive processing probably through 5HT3 receptors. Patients suffering chronic pain originating from deep tissues, such as temporo-mandibular disorder, fibromyalgia, or low back pain, often complain of pain and tenderness in various parts of the body. We injected complete Freund's adjuvant into a temporo-mandibular joint of rats unilaterally, and then injected 5% formalin into the ipsilateral or contralateral masseter muscle 2 weeks later. Pain-related behavior and neuronal activation in the spinal trigeminal nucleus were enhanced on both sides compared to those in non-inflammatory controls. Systemic enhancement of pain and hyperalgesia induced by unilateral joint inflammation may have been caused by the central sensitization and descending facilitation.